Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 2028  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
  »  Article in PDF (650 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

  In this Article
 »  References
 »  Article Figures

 Article Access Statistics
    PDF Downloaded40    
    Comments [Add]    
    Cited by others 1    

Recommend this journal


Table of Contents    
Year : 2017  |  Volume : 65  |  Issue : 1  |  Page : 166-167

Dural venous sinus thrombosis following intravitreal bevacizumab

Department of Neurology, Comprehensive Stroke Care Program, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India

Date of Web Publication12-Jan-2017

Correspondence Address:
Dr. P N Sylaja
Department of Neurology, Comprehensive Stroke Care Program, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0028-3886.198223

Rights and Permissions

How to cite this article:
Maniangatt SC, Trivedi M, Sreedharan SE, Jayadevan E R, Sylaja P N. Dural venous sinus thrombosis following intravitreal bevacizumab. Neurol India 2017;65:166-7

How to cite this URL:
Maniangatt SC, Trivedi M, Sreedharan SE, Jayadevan E R, Sylaja P N. Dural venous sinus thrombosis following intravitreal bevacizumab. Neurol India [serial online] 2017 [cited 2020 Jul 3];65:166-7. Available from:


Bevacizumab, used in cancer therapy, is known to be associated with an increased risk of venous and arterial thromboembolism.[1],[2] There are rare reports of cerebral sinus venous thrombosis with intravenous bevacizumab during cancer therapy.[3],[4] Intravitreal bevacizumab is a promising treatment in proliferative diabetic retinopathy. We present a case of cerebral venous sinus thrombosis in a 64-year-old man during treatment with intravitreal bevacizumab, which has not been reported previously in the literature.

A 64-year-old male patient with a history of Paget's disease and coronary artery disease (that developed in 2009), reported an acute-onset blurring of vision in the left eye in 2011, and was diagnosed to be having macular degeneration along with retinal hemorrhage, He underwent vitrectomy and the antiplatelet medication was stopped. Since then, he had recurrent episodes of worsening of vision either in the left or right eye, for which he was treated with intravitreal monoclonal antibody injection. He had received 9 such injections of rancizumab and bevacizumab in the last 12 months. He presented to us with a history of moderate intensity headache with no associated vomiting or blurring of vision for one week. Six days later, he noted acute onset of giddiness with no true vertigo, vomiting, weakness, slurring of speech, or gait unsteadiness. On examination, he was conscious, his fundus was normal, and there was no focal neurological deficit. His computed tomogram (CT) of the brain was normal. CT venogram showed extensive thrombosis of the superior sagittal sinus, bilateral transverse sinuses (left > right), left sigmoid sinus, and left internal jugular vein [Figure 1]a and [Figure 1]b. Magnetic resonance imaging (MRI) of the brain, diffusion weighted imaging, showed no evidence of an acute infarct. A diagnosis of cerebral venous sinus thrombosis was made and he was started on anticoagulant therapy. Diagnostic workup for malignancy and vasculitic workup were negative. Serum homocysteine, protein S, protein C, and antithrombin III were normal. He was started initially on anticoagulation with heparin and then administered oral anticoagulant medication, warfarin.
Figure 1: (a) Computed tomography (CT) venogram mid-sagittal image showing thrombosis involving the entire length of superior sagittal sinus. (b) CT venogram axial image showing thrombosis involving the left transverse sinus

Click here to view

Venous thromboembolism is reported in 3–19% of patients treated with intravenous bevacizumab for malignancy.[1],[2] A recent meta-analysis of 15 randomized controlled trials confirmed the increased risk of venous thromboembolism in cancer patients receiving this drug.[1] Rare studies of dural venous sinus thrombosis (DSVT) have been reported with bevacizumab. In our patient, the risk factors for DSVT, such as a prothrombotic state or malignancy, were negative. Our patient received only intravitreal bevacizumab using multiple injections. Considering the risk of thrombosis with bevacizumab, we attribute the DSVT to be caused by this drug. Bevacizumab is a recombinant, humanized, monoclonal neutralizing antibody against vascular endothelial growth factor (VEGF) used in the treatment of malignancy and is administered intravenously. Venous thrombosis results from the anti-VEGF effect of bevacizumab, which increases the blood viscosity and hematocrit by overproduction of erythropoietin, leading to thrombosis. It also exposes the subendothelial procoagulant phospholipids, leading to thrombosis by inhibiting VEGF-induced endothelial regeneration. This case report suggests that physicians should be aware of the risk of DVST on treatment with intravitreal bevacizumab, and that the patients who receive this medication need to be closely monitored during treatment.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

 » References Top

Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA 2008;300:2277-85.  Back to cited text no. 1
Hurwitz HI, Saltz LB, Van Cutsem E, Cassidy J, Wiedemann J, Sirzén F, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011;29:1-11.  Back to cited text no. 2
Ozen A, Cicin I, Sezer A, Uzunoglu S, Saynak M, Genchellac H, et al. Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab. J Cancer Res Ther 2009;5:130-2.  Back to cited text no. 3
Vargo JA, Snelling BM, Ghareeb ER, John K, Frame JN, Schmidt JH, et al. Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab. J Neurooncol 2011;104:595-8.  Back to cited text no. 4


  [Figure 1]

This article has been cited by
1 Bevacizumab
Reactions Weekly. 2017; 1645(1): 60
[Pubmed] | [DOI]


Print this article  Email this article
Online since 20th March '04
Published by Wolters Kluwer - Medknow